



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 25, 2015

Via E-Mail

Erik Ostrowski  
Chief Financial Officer  
Summit Therapeutics plc  
85b Park Drive  
Milton Park, Abingdon  
Oxfordshire OX14 4RY  
United Kingdom

**Re: Summit Therapeutics plc  
Amendment No. 1 to  
Registration Statement on Form F-1  
Filed February 20, 2015  
File No. 333-201807**

Dear Mr. Ostrowski:

We have reviewed your amended registration statement and have the following comment.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our February 10, 2015 letter.

Exhibit 5.1

1. Legal counsel should revise Exhibit 5.1 to remove the entire last sentence of the opinion which reads "Our liability in giving this opinion is limited to you, our client, and our consent is not to be taken as an acknowledgement that we accept liability to any person other than you, our client."

You may contact Vanessa Robertson at (202) 551-3649 or Mark Brunhofer at (202) 551-3638 if you have questions regarding comments on the financial statements and related matters. Please contact Preston Brewer at (202) 551-3969 or me at (202) 551-3715 with any other questions.

Erik Ostrowski  
Summit Therapeutics plc  
February 25, 2015  
Page 2

Sincerely,

/s/ Jeffrey P. Riedler

Jeffrey P. Riedler  
Assistant Director

cc: Via E-Mail  
Brian A. Johnson, Esq.  
David E. Redlick, Esq.  
Wilmer Cutler Pickering Hale and Dorr LLP